|
|
相关文章推荐
|
Your browser does not support the NLM PubReader view. Go to this page to see a list of supported browsers or return to the Article in classic view . |
Making articles easier to read in PMC
We are experimenting with display styles that make it easier to read articles in PMC. The ePub format uses eBook readers, which have several "ease of reading" features already built in. The ePub format is best viewed in the iBooks reader. You may notice problems with the display of certain parts of an article in other eReaders. Generating an ePub file may take a long time, please be patient.
Welcome to PubReader!
Click on
above to:
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family.
Annu Rev Immunol.
2009;
27
:519–550.
[
PubMed
]
[
Google Scholar
]
•• Provides a comprehensive review of the IL-1 family
4.
Eisenbarth SC, Flavell RA. Innate instruction of adaptive immunity revisited. The inflammasome.
EMBO Mol Med.
2009;
1
(2):92–98.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
5.
Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines.
Immunol Rev.
2008;
223
:20–38.
[
PubMed
]
[
Google Scholar
]
6.
Sims JE, Nicklin MJ, Bazan JF, Barton JL, Busfield SJ, Ford JE, Kastelein RA, Kumar S, Lin H, Mulero JJ, Pan J, et al. A new nomenclature for IL-1-family genes.
Trends Immunol.
2001;
22
(10):536–537.
[
PubMed
]
[
Google Scholar
]
•• A must-have reference listing all the different names the IL-1 family members have been assigned over the years.
7.
Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE. Four new members expand the interleukin-1 superfamily.
J Biol Chem.
2000;
275
(2):1169–1175.
[
PubMed
]
[
Google Scholar
]
8.
Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S, Wagner J, Edwards G, Clifford T, Menon S, Bazan JF, et al. Two novel IL-1 family members, IL-1S and IL-lε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2.
J Immunol.
2001;
167
(3):1440–1446.
[
PubMed
]
[
Google Scholar
]
9.
Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, Yansura D, Lewis L, Eigenbrot C, Henzel WJ, Vandlen R. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/ IL-lRrp.
Cytokine.
2001;
13
(1):1–7.
[
PubMed
]
[
Google Scholar
]
10.
Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, Hansen D, Schweighofer K, Mize NK, Ford JE. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member.
J Biol Chem.
2001;
276
(23):20597–20602.
[
PubMed
]
[
Google Scholar
]
11.
Mulero JJ, Pace AM, Nelken ST, Loeb DB, Correa TR, Drmanac R, Ford JE. IL1HY1: A novel interleukin-1 receptor antagonist gene.
Biochem Biophys Res Commun.
1999;
263
(3):702–706.
[
PubMed
]
[
Google Scholar
]
12.
Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE, Capper EA, Tal-Singer R, Wells GI, Doyle ML, Young PR. Identification and initial characterization of four novel members of the interleukin-1 family.
J Biol Chem.
2000;
275
(14):10308–10314.
[
PubMed
]
[
Google Scholar
]
13.
Barton JL, Herbst R, Bosisio D, Higgins L, Nicklin MJ. A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1RA, IL-18 and IL-18 antagonist activities.
Eur J Immunol.
2000;
3O
(ll):3299–3308.
[
PubMed
]
[
Google Scholar
]
14.
Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-lRrp2 and IL-lRAcP to activate the pathway leading to NF-κB and MAPKs.
J Biol Chem.
2004;
279
(14):13677–13688.
[
PubMed
]
[
Google Scholar
]
15.
Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, Dinarello CA, Kim SH. A complex of the IL-1 homologue IL-lF7b and IL-18-binding protein reduces IL-18 activity.
Proc Natl Acad Sci USA.
2002;
99
(21):13723–13728.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
16.
Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, Kanaly ST, Towne JE, Willis CR, Kuechle MK, Sims JE, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation.
J Exp Med.
2007;
204
(11):2603–2614.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
•• The first report of an in vivo function for IL-1F6, the induction of a psoriasis-like phenotype in mice
17.
Dunn EF, Gay NJ, Bristow AF, Gearing DP, O'Neill LA, Pei XY. High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity.
Biochemistry.
2003;
42
(37):10938–10944.
[
PubMed
]
[
Google Scholar
]
18.
Costelloe C, Watson M, Murphy A, McQuillan K, Loscher C, Armstrong ME, Garlanda C, Mantovani A, O'Neill LAJ, Mills KHG, Lynch MA. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8.
J Neurochem.
2008;
l05
(5):1960–1969.
[
PubMed
]
[
Google Scholar
]
19.
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.
Immunity.
2005;
23
(5):479–490.
[
PubMed
]
[
Google Scholar
]
20.
Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells
in vivo:
A novel 'alarmin'?
PLoS ONE.
2008;
3
(10):e3331.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
• Describes the tissue distribution of IL-33, in particular the high constitutive expression of this molecule in keratinocytes
21.
Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells.
Proc Natl Acad Sci USA.
2007;
104
(47):18660–18665.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
22.
Smith DE. IL-33: A tissue derived cytokine pathway involved in allergic inflammation and asthma.
Clin Exp Allergy.
2010;
4O
(2):200–208.
[
PubMed
]
[
Google Scholar
]
23.
Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical Th2-type response.
J Allergy Clin Immunol.
2009;
123
(5):1047–1054.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
24.
Mayuzumi N, Matsushima H, Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production.
Eur J Immunol.
2009;
39
(12):3331–3342.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
25.
Wang T, Bird S, Koussounadis A, Holland JW, Carrington A, Zou J, Secombes CJ. Identification of a novel IL-1 cytokine family member in teleost fish.
J Immunol.
2009;
183
(2):962–974.
[
PubMed
]
[
Google Scholar
]
26.
Goldbach-Mansky R, Kastner DL. Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.
J Allergy Clin Immunol.
2009;
124
(6):1141–1149.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
27.
Iversen L, Johansen C. Inflammasomes and inflammatory caspases in skin inflammation.
Expert Rev Mol Diagn.
2008;
8
(6):697–705.
[
PubMed
]
[
Google Scholar
]
• • Provides a concise introduction to the inflammasome, and reviews the potential involvement of this complex in skin disease
28.
Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, Voronov E, Martin MU, Dinarello CA, Apte RN. Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation.
Proc Natl Acad Sci USA.
2010;
107
(6):2574–2579.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
29.
Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S. Mature interleukin-33 is produced by calpain-mediated cleavage
in vivo
.
Biochem Biophys Res Commun.
2009;
387
(1):218–222.
[
PubMed
]
[
Google Scholar
]
30.
Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, Okumura K, Saito H, Nakae S. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages.
J Immunol.
2009;
183
(12):7890–7897.
[
PubMed
]
[
Google Scholar
]
31.
Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, Lavelle EC, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.
Immunity.
2009;
31
(1):84–98.
[
PubMed
]
[
Google Scholar
]
32.
Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage.
J Biol Chem.
2009;
284
(29):19420–19426.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
33.
Cayrol C, Girard J-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1.
Proc Natl Acad Sci USA.
2009;
106
(22):9021–9026.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
34.
Carriere V, Roussel L, Ortega N, Lacorre D-A, Americh L, Aguilar L, Bouche G, Girard J-P. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor
in vivo
.
Proc Natl Acad Sci USA.
2007;
104
(1):282–287.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
35.
Martin U, Scholler J, Gurgel J, Renshaw B, Sims JE, Gabel CA. Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages.
J Immunol.
2009;
183
(6):4021–4030.
[
PubMed
]
[
Google Scholar
]
36.
Luheshi NM, Rothwell NJ, Brough D. Dual functionality of interleukin-1 family cytokines: Implications for anti-interleukin-1 therapy.
Br J Pharmacol.
2009;
157
(8):1318–1329.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
37.
Sharma S, Kulk N, Nold MF, Graf R, Kim S-H, Reinhardt D, Dinarello CA, Bufler P. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines.
J Immunol.
2008;
180
(8):5477–5482.
[
PubMed
]
[
Google Scholar
]
38.
Wittmann M, Macdonald A, Renne J. IL-18 and skin inflammation.
Autoimmun Rev.
2009;
9
(1):45–48.
[
PubMed
]
[
Google Scholar
]
39.
Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease.
Annu Rev Immunol.
2009;
27
:621–668.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
40.
Oyoshi MK, He R, Kumar L, Yoon J, Geha RS. Cellular and molecular mechanisms in atopic dermatitis. In: Alt FW, editor.
Advances in Immunology.
Maryland Heights, MO, USA: Academic Press; 2009. pp. 135–226. [
PubMed
]
[
Google Scholar
]
41.
Ludwig R, Schmidt E. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?
G Ital Dermatol Venereol.
2009;
144
(4):339–349.
[
PubMed
]
[
Google Scholar
]
42.
Ertam I, Itirli G, Onay H, Alper S, Ozkinay F. Interleukin-1 receptor antagonist and tumour necrosis factor-α gene polymorphisms in turkish patients with allergic contact dermatitis.
Contact Dermatitis.
2009;
61
(2):86–90.
[
PubMed
]
[
Google Scholar
]
43.
Oudot T, Lesueur F, Guedj M, de Cid R, McGinn S, Heath S, Foglio M, Prum B, Lathrop M, Prud'homme J-F, Fischer J. An association study of 22 candidate genes in psoriasis families reveals shared genetic factors with other autoimmune and skin disorders.
J Invest Dermatol.
2009;
129
(11):2637–2645.
[
PubMed
]
[
Google Scholar
]
44.
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham T-H, Booty M, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
N Engl J Med.
2009;
360
(23):2426–2437.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
45.
Janssens AS, Pavel S, Tensen CP, Teunissen MB, Out-Luiting JJ, Willemze R, Gruijl FR. Reduced IL-1RA/IL-1 ratio in ultraviolet B-exposed skin of patients with polymorphic light eruption.
Exp Dermatol.
2009;
18
(3):212–217.
[
PubMed
]
[
Google Scholar
]
46.
Faustin B, Reed JC. Sunburned skin activates inflammasomes.
Trends Cell Biol.
2008;
18
(1):4–8.
[
PubMed
]
[
Google Scholar
]
47.
Kirschner N, Poetzl C, von den Driesch P, Wladykowski E, Moll I, Behne MJ, Brandner JM. Alteration of tight junction proteins is an early event in psoriasis: Putative involvement of proinflammatory cytokines.
Am J Pathol.
2009;
175
(3):1095–1106.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
48.
Sanmiguel JC, Olaru F, Li J, Mohr E, Jensen LE. Interleukin-1 regulates keratinocyte expression of T cell targeting chemokines through interleukin-1 receptor associated kinase-1 (IRAKI) dependent and independent pathways.
Cell Signal.
2009;
21
(5):685–694.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
49.
Renne J, Schäfer V, Werfel T, Wittmann M. Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation.
Br J Dermatol.
2010
doi:j.1365-2133.2010.09662.x. [
PubMed
]
[
Google Scholar
]
50.
Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, Schwertschlag U, Dorner AJ, Krueger JG, Trepicchio WL. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling.
Pharmacogenomics J.
2001;
1
(4):272–287.
[
PubMed
]
[
Google Scholar
]
• Reports a comprehensive microarray study of differential gene expression, including that of IRAK1
51.
Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J, Fernandez-Vina MA, Menter A. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies.
Hum Mol Genet.
2001;
l0
(17):1793–1805.
[
PubMed
]
[
Google Scholar
]
52.
Zhou X, Krueger JG, Kao M-CJ, Lee E, Du F, Menter A, Wong WH, Bowcock AM. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array.
Physiol Genomics.
2003;
13
(l):69–78.
[
PubMed
]
[
Google Scholar
]
•• The first microarray study to observe upregulation of IL-1F9 mRNA in psoriatic skin; increased expression of IRAK1 was also observed.
53.
Gruaz D, Didierjean L, Grassi J, Frobert Y, Dayer JM, Saurat JH. Interleukin 1 α and β in psoriatic skin: Enzymoimmunoassay, immunoblot studies and effect of systemic retinoids.
Dermatologica.
1989;
179
(4):202–206.
[
PubMed
]
[
Google Scholar
]
54.
Serwin AB, Sokolowska M, Chodynicka B. Soluble tumor necrosis factor α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.
Photodermatol Photoimmunol Photomed.
2005;
21
(4):210–211.
[
PubMed
]
[
Google Scholar
]
55.
Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
J Immunol.
2005;
175
(4):2721–2729.
[
PubMed
]
[
Google Scholar
]
56.
Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: A key inflammatory mediator in psoriasis?
Cytokine.
2006;
33
(2):72–78.
[
PubMed
]
[
Google Scholar
]
57.
Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N, Ebe K, Tanaka K, Sugiura H, Nakashima K, Tamari M, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis.
Hum Mol Genet.
2005;
14
(19):2919–2927.
[
PubMed
]
[
Google Scholar
]
• Demonstrated an association between atopic dermatitis and polymorphisms in the ST2 gene, implicating IL-33-ST2 signaling in the pathology of this disorder
58.
Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, Chaudhary D. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.
Inflamm Res.
2010;
59
(3):207–218.
[
PubMed
]
[
Google Scholar
]
59.
Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A, L iew FY, Melendez AJ. The cytokine interleukin-33 mediates anaphylactic shock.
Proc Natl Acad Sci USA.
2009;
106
(24):9773–9778.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
Retracted
60.
Hartmann B, Staedtler F, Hartmann N, Meingassner J, Firat H. Gene expression profiling of skin and draining lymph nodes of rats affected with cutaneous contact hypersensitivity.
Inflamm Res.
2006;
55
(8):322–334.
[
PubMed
]
[
Google Scholar
]
61.
Manetti M, Ibba-Manneschi L, Liakouli V, Guiducci S, Milia AF, Benelli G, Marrelli A, Conforti ML, Romano E, Giacomelli R, Matucci-Cerinic M, et al. The ILl-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis.
Ann Rheum Dis.
2010;
69
(3):598–605.
[
PubMed
]
[
Google Scholar
]
62.
Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production.
Blood.
2009;
114
(14):3117–3126.
[
PubMed
]
[
Google Scholar
]
63.
Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos K-D, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.
Proc Natl Acad Sci USA.
2010;
107
(9):4448–4453.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
• The first study to demonstrate increased levels of IL-33 in affected and unaffected psoriatic skin
64.
Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, Bourne PA, Pierce RH, Kastelein R, Pflanz S. IL-33 induces IL-13-dependent cutaneous fibrosis.
J Immunol.
2009;
184
(3):1526–1535.
[
PubMed
]
[
Google Scholar
]
65.
Verri WA, Jr, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Ferreira SH, Liew FY, Cunha FQ. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice.
Proc Natl Acad Sci USA.
2008;
105
(7):2723–2728.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
66.
Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, Ghosh D, Aphale A, Gumucio DL, Voorhees JJ, Abecasis GR, et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin.
J Invest Dermatol.
2009;
129
(12):2795–2804.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
67.
Kamsteeg M, Jansen PA, Vlijmen-Willems IM, Erp PE, Rodijk-Olthuis D, Valk PG, Feuth T, Zeeuwen PL, Schalkwijk J. Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis.
Br J Dermatol.
2010;
162
(3):568–578.
[
PubMed
]
[
Google Scholar
]
•• The first paper to report upregulation of IL-1F9 mRNA expression in atopic and contact dermatitis, in addition to psoriasis
68.
Geusens B, Sanders N, Prow T, Van Gele M, Lambert J. Cutaneous short-interfering RNA therapy.
Expert Opin Drug Deliv.
2009;
6
(12):1333–1349.
[
PubMed
]
[
Google Scholar
]
69.
Zhang ZX, Beduhn ME, Zheng X, Min WP, Jevnikar AM. Preventing tissue injury using siRNA.
Methods Mol Biol.
2010;
623
:341–355.
[
PubMed
]
[
Google Scholar
]
•• Provides a review of RNAi technology
70.
Moltó A, Olivé A. Anti-IL-1 molecules: New comers and new indications.
Joint Bone Spine.
2010;
77
(2):102–107.
[
PubMed
]
[
Google Scholar
]
71.
Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases.
Curr Opin Investig Drugs.
2009;
l0
(11):1204–1211.
[
PubMed
]
[
Google Scholar
]
72.
Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma.
Biochem Biophys Res Commun.
2009;
386
(1):181–185.
[
PubMed
]
[
Google Scholar
]
73.
Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.
Immunity.
2003;
18
(1):87–96.
[
PubMed
]
[
Google Scholar
]
74.
Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Cytokine traps, et al. Multi-component, high-affinity blockers of cytokine action.
Nat Med.
2003;
9
(1):47–52.
[
PubMed
]
[
Google Scholar
]
•• Describes the approach to designing novel decoy receptors
Dinarello C. Setting the cytokine trap for autoimmunity. Nat Med. 2003; 9 (1):20–22. [ PubMed ] [ Google Scholar ] • Provides illustrations to help understand the engineered proteins reported in reference [ 74 ]
Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol. 2000; 164 (10):5277–5286. [ PubMed ] [ Google Scholar ] • The first study to demonstrate an anti-inflammatory function for sIL-1RAcP
Dinarello C. Setting the cytokine trap for autoimmunity. Nat Med. 2003; 9 (1):20–22. [ PubMed ] [ Google Scholar ] • Provides illustrations to help understand the engineered proteins reported in reference [ 74 ]
Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol. 2000; 164 (10):5277–5286. [ PubMed ] [ Google Scholar ] • The first study to demonstrate an anti-inflammatory function for sIL-1RAcP
77.
Jensen LE, Whitehead AS. Expression of alternatively spliced interleukin-1 receptor accessory protein mrnas is differentially regulated during inflammation and apoptosis.
Cell Signal.
2003;
15
(8):793–802.
[
PubMed
]
[
Google Scholar
]
78.
Le GT, Abbenante G. Inhibitors of tace and caspase-1 as anti-inflammatory drugs.
Curr Med Chem.
2005;
12
(25):2963–2977.
[
PubMed
]
[
Google Scholar
]
79.
Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: Dermatological indications, mechanisms of action and side-effects.
Br J Dermatol.
2005;
153
(2):254–273.
[
PubMed
]
[
Google Scholar
]
80.
Keller M, Sollberger G, Beer H-D. Thalidomide inhibits activation of caspase-1.
J Immunol.
2009;
183
(9):5593–5599.
[
PubMed
]
[
Google Scholar
]
•• Suggests that thalidomide metabolites may provide a starting point for the development of novel caspase-1 inhibitors
推荐文章